Pulmonary embolism, coagulation
| Zeile 36: | Zeile 36: | ||
| − | + | ||
{{tp|p=32212240|t=2020. Disseminated intravascular coagulation in patients with 2019?nCoV pneumonia |pdf=|usr=}} | {{tp|p=32212240|t=2020. Disseminated intravascular coagulation in patients with 2019?nCoV pneumonia |pdf=|usr=}} | ||
{{tp|p=32073213|t=2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia |pdf=|usr=}} | {{tp|p=32073213|t=2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | {{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | ||
{{tp|p=32246317|t=ä. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 |pdf=|usr=}} | {{tp|p=32246317|t=ä. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 |pdf=|usr=}} | ||
| Zeile 52: | Zeile 52: | ||
| − | + | ||
{{tp|p=32268022|t=ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 |pdf=|usr=}} | {{tp|p=32268022|t=ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 |pdf=|usr=}} | ||
| Zeile 60: | Zeile 60: | ||
{{tp|p=32335420|t=ä. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients |pdf=|usr=}} | {{tp|p=32335420|t=ä. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients |pdf=|usr=}} | ||
| − | + | ||
{{tp|p=C7146714|t=ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | {{tp|p=C7146714|t=ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 |pdf=|usr=}} | ||
| Zeile 67: | Zeile 67: | ||
| − | + | ||
{{tp|p=32374029|t=2020. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis |pdf=|usr=}} | {{tp|p=32374029|t=2020. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis |pdf=|usr=}} | ||
{{tp|p=32369614|t=2020. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia |pdf=|usr=}} | {{tp|p=32369614|t=2020. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia |pdf=|usr=}} | ||
| Zeile 74: | Zeile 74: | ||
{{ttp|p=32330308|t=2020. COVID19 coagulopathy in Caucasian patients |pdf=|usr=}} | {{ttp|p=32330308|t=2020. COVID19 coagulopathy in Caucasian patients |pdf=|usr=}} | ||
{{ttp|p=32304581|t=2020. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis |pdf=|usr=}} | {{ttp|p=32304581|t=2020. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| Zeile 85: | Zeile 85: | ||
| − | + | ||
{{tp|p=32379935|t=2020. Response to "Lupus anticoagulant is frequent in patients with Covid-19" |pdf=|usr=}} | {{tp|p=32379935|t=2020. Response to "Lupus anticoagulant is frequent in patients with Covid-19" |pdf=|usr=}} | ||
{{tp|p=32379918|t=2020. Coagulopathy of COVID-19 and antiphospholipid antibodies |pdf=|usr=}} | {{tp|p=32379918|t=2020. Coagulopathy of COVID-19 and antiphospholipid antibodies |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32302438|t=2020. Hypercoagulability of COVID-19 patients in Intensive Care Unit A Report of Thromboelastography Findings and other Parameters of Hemostasis |pdf=|usr=}} | {{tp|p=32302438|t=2020. Hypercoagulability of COVID-19 patients in Intensive Care Unit A Report of Thromboelastography Findings and other Parameters of Hemostasis |pdf=|usr=}} | ||
{{tp|p=32344457|t=2020. Uncertainties on the prognostic value of D-dimers in COVID-19 patients |pdf=|usr=}} | {{tp|p=32344457|t=2020. Uncertainties on the prognostic value of D-dimers in COVID-19 patients |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32324960|t=2020. Laboratory haemostasis monitoring in COVID-19 |pdf=|usr=}} | {{tp|p=32324960|t=2020. Laboratory haemostasis monitoring in COVID-19 |pdf=|usr=}} | ||
{{tp|p=32324958|t=2020. Lupus anticoagulant is frequent in patients with Covid-19 |pdf=|usr=}} | {{tp|p=32324958|t=2020. Lupus anticoagulant is frequent in patients with Covid-19 |pdf=|usr=}} | ||
| Zeile 110: | Zeile 103: | ||
{{tp|p=32302453|t=2020. Thromboinflammation and the hypercoagulability of COVID-19 |pdf=|usr=}} | {{tp|p=32302453|t=2020. Thromboinflammation and the hypercoagulability of COVID-19 |pdf=|usr=}} | ||
{{ttp|p=32302448|t=2020. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome |pdf=|usr=}} | {{ttp|p=32302448|t=2020. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome |pdf=|usr=}} | ||
| − | |||
| − | + | ||
| − | + | ||
{{tp|p=32359410|t=ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT |pdf=|usr=}} | {{tp|p=32359410|t=ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT |pdf=|usr=}} | ||
| Zeile 130: | Zeile 122: | ||
{{tp|p=32378030|t=ä. COVID-19-Related Stroke |pdf=|usr=}} | {{tp|p=32378030|t=ä. COVID-19-Related Stroke |pdf=|usr=}} | ||
{{tp|p=32279286|t=2020. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring |pdf=|usr=}} | {{tp|p=32279286|t=2020. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring |pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32316063|t=2020. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure |pdf=|usr=}} | {{tp|p=32316063|t=2020. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure |pdf=|usr=}} | ||
{{tp|p=32374920|t=2020. Viscoelastic testing in COVID-19: a possible screening tool for severe disease?|pdf=|usr=}} | {{tp|p=32374920|t=2020. Viscoelastic testing in COVID-19: a possible screening tool for severe disease?|pdf=|usr=}} | ||
| Zeile 140: | Zeile 132: | ||
{{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32283877|t=2020. Prognostic value of myocardial injury in patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32344469|t=2020. DIC in COVID-19: Implications for Prognosis and Treatment?|pdf=|usr=}} | {{tp|p=32344469|t=2020. DIC in COVID-19: Implications for Prognosis and Treatment?|pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
{{tp|p=32418867|t=ä. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept |pdf=|usr=}} | {{tp|p=32418867|t=ä. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept |pdf=|usr=}} | ||
| Zeile 148: | Zeile 140: | ||
{{tp|p=32414639|t=ä. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?|pdf=|usr=}} | {{tp|p=32414639|t=ä. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?|pdf=|usr=}} | ||
| − | + | ||
| − | + | ||
| − | + | ||
{{tp|p=32402423|t=2020. Ten key points that vascular doctors learned very quickly about COVID-19 |pdf=|usr=}} | {{tp|p=32402423|t=2020. Ten key points that vascular doctors learned very quickly about COVID-19 |pdf=|usr=}} | ||
{{tp|p=32417015|t=ä. Risk of peripheral arterial thrombosis in COVID-19 |pdf=|usr=}} | {{tp|p=32417015|t=ä. Risk of peripheral arterial thrombosis in COVID-19 |pdf=|usr=}} | ||
Version vom 11. Juni 2020, 10:11 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Since there are many organ manifestations of Hypercoagulation, subcategorization and tranccategorization was applied.
- Venous thrombosis
- Pulmonary embolism
- Cerebral embolism
- Myocardial infarction
- Arterial embolism
- Microembolism
- Hypercoagulation
- Antiphospholipid antibodies
- Disseminated intravascular coagulation
- Bleeding
- Labwork of Thrombembolism
- Prophylaxis of Thrombembolism
The unifying concept behind is Dysendoheliosis with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.
32360432 ä. Acute thrombosis of an aortic prosthetic graft in a patient with severe COVID-19 related pneumonia
32350161 2020. Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32250159 2020. Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients
32357997 2020. Coagulopathy associated with COVID-19
32334995 2020. Concomitant acute aortic thrombosis and pulmonary embolism complicating COVID-19 pneumonia
32338707 ä. Acute pulmonary embolism in conjunction with intramural right ventricular thrombus in a SARS-CoV-2-positive patient
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
32212240 2020. Disseminated intravascular coagulation in patients with 2019?nCoV pneumonia
32073213 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
32338320 ä. Covid-19 treatment update: follow the scientific evidence
32246317 ä. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2
32306290 ä. Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report
32360371 ä. Thromboembolic events in patients with SARS-CoV-2
32360679 ä. Acute limb ischemia in patients with COVID-19 pneumonia
32360372 ä. An increased severity of peripheral arterial disease in the covid-19 era
32361070 2020. Cardiovascular examination should also include peripheral arterial evaluation for COVID-19 patients
32268022 ä. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
32351657 ä. Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia
32353746 2020. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy
32335420 ä. Age-adjusted D-dimer cut-off levels to rule out venous thromboembolism in COVID-19 patients
C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32267008 2020. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability
32374029 2020. Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis
32369614 2020. Concomitant haemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukaemia
| 32369610 2020. Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily |
32353183 2020. Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19
| 32330308 2020. COVID19 coagulopathy in Caucasian patients |
| 32304581 2020. Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis |
32172226 2020. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
32333581 2020. Contrast enhanced ultrasonography (CEUS) to detect abdominal microcirculatory disorders in severe cases of COVID-19 infection: First experience
32333579 2020. (clin-hemorheol-microcirc) COVID-19
| 32294809 2020. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis |
32379935 2020. Response to "Lupus anticoagulant is frequent in patients with Covid-19"
32379918 2020. Coagulopathy of COVID-19 and antiphospholipid antibodies
32302438 2020. Hypercoagulability of COVID-19 patients in Intensive Care Unit A Report of Thromboelastography Findings and other Parameters of Hemostasis
32344457 2020. Uncertainties on the prognostic value of D-dimers in COVID-19 patients
32324960 2020. Laboratory haemostasis monitoring in COVID-19
32324958 2020. Lupus anticoagulant is frequent in patients with Covid-19
32306492 2020. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32302459 2020. COVID-19 and acute coagulopathy in pregnancy
32302453 2020. Thromboinflammation and the hypercoagulability of COVID-19
| 32302448 2020. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome |
32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
32369280 ä. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19
32367765 2020. Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count
32367749 2020. Transient appearance of EDTA dependent pseudothrombocytopenia in a patient with 2019 novel coronavirus pneumonia
32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands
32324099 2020. Pulmonary, Cerebral, and Renal Thromboembolic Disease Associated with COVID-19 Infection
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
32378030 ä. COVID-19-Related Stroke
32279286 2020. Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring
32316063 2020. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure
32374920 2020. Viscoelastic testing in COVID-19: a possible screening tool for severe disease?
32220276 2020. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32133824 2020. COVID-19 complicated with DIC: 2 cases report and literatures review
32283877 2020. Prognostic value of myocardial injury in patients with COVID-19
32344469 2020. DIC in COVID-19: Implications for Prognosis and Treatment?
32418867 ä. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept
C7196387 ä. Extensive aortic thrombosis in a patient with Covid-19
32414639 ä. Bleeding in COVID-19 severe pneumonia: The other side of abnormal coagulation pattern?
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32417015 ä. Risk of peripheral arterial thrombosis in COVID-19
32423583 2020. Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19
C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
32407937 2020. The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China
| 32403033 2020. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid |
32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
